Rusfertide for Polycythemia Vera
(THRIVE Trial)
Trial Summary
What is the purpose of this trial?
The goal of this clinical trial is to assess long-term safety and efficacy of rusfertide in subjects with polycythemia vera. Subjects who complete dosing with rusfertide until the end-of-treatment visit of a Phase 2 rusfertide study and meet the inclusion/exclusion criteria for this study, are eligible to participate in this open-label study and continue treatment with rusfertide.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot use other investigational treatments during the study or within 28 days after the last rusfertide dose.
How is the drug rusfertide unique for treating polycythemia vera?
Rusfertide is unique because it is a novel treatment specifically designed to manage polycythemia vera, a condition with limited standard treatment options. It works by reducing the production of red blood cells, which is different from other treatments that may focus on managing symptoms or complications.12345
Eligibility Criteria
This trial is for people with Polycythemia Vera who have already been treated with rusfertide for at least 12 months in a previous Phase 2 or Phase 3 study. Participants must understand the study, be willing to follow its rules, and give written consent.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants continue treatment with rusfertide to assess long-term safety and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Open-label rusfertide
Find a Clinic Near You
Who Is Running the Clinical Trial?
Protagonist Therapeutics, Inc.
Lead Sponsor